These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 28392484)
1. Use of CRISPR/Cas9 to model brain diseases. Yan S; Tu Z; Li S; Li XJ Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():488-492. PubMed ID: 28392484 [TBL] [Abstract][Full Text] [Related]
2. Applications of CRISPR-Cas9 in Alzheimer's Disease and Related Disorders. De Plano LM; Calabrese G; Conoci S; Guglielmino SPP; Oddo S; Caccamo A Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955847 [TBL] [Abstract][Full Text] [Related]
3. Advances in Sphingolipidoses: CRISPR-Cas9 Editing as an Option for Modelling and Therapy. Santos R; Amaral O Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771289 [TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9: from Genome Editing to Cancer Research. Chen S; Sun H; Miao K; Deng CX Int J Biol Sci; 2016; 12(12):1427-1436. PubMed ID: 27994508 [TBL] [Abstract][Full Text] [Related]
6. Genetically modified pig models for neurodegenerative disorders. Holm IE; Alstrup AK; Luo Y J Pathol; 2016 Jan; 238(2):267-87. PubMed ID: 26446984 [TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy. Zhang X; Wang L; Liu M; Li D Sci China Life Sci; 2017 May; 60(5):468-475. PubMed ID: 28534255 [TBL] [Abstract][Full Text] [Related]
8. Mosaicism in CRISPR/Cas9-mediated genome editing. Mehravar M; Shirazi A; Nazari M; Banan M Dev Biol; 2019 Jan; 445(2):156-162. PubMed ID: 30359560 [TBL] [Abstract][Full Text] [Related]
10. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases. Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL Neurochem Int; 2018 Jan; 112():187-196. PubMed ID: 28732771 [TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 Technology as a Modern Genetic Manipulation Tool for Recapitulating of Neurodegenerative Disorders in Large Animal Models. Barazesh M; Mohammadi S; Bahrami Y; Mokarram P; Morowvat MH; Saidijam M; Karimipoor M; Kavousipour S; Vosoughi AR; Khanaki K Curr Gene Ther; 2021; 21(2):130-148. PubMed ID: 33319680 [TBL] [Abstract][Full Text] [Related]
12. Development and application of CRISPR/Cas9 technologies in genomic editing. Zhang C; Quan R; Wang J Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822 [TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9-mediated correction of human genetic disease. Men K; Duan X; He Z; Yang Y; Yao S; Wei Y Sci China Life Sci; 2017 May; 60(5):447-457. PubMed ID: 28534256 [TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9: an advanced tool for editing plant genomes. Samanta MK; Dey A; Gayen S Transgenic Res; 2016 Oct; 25(5):561-73. PubMed ID: 27012546 [TBL] [Abstract][Full Text] [Related]
16. CRISPR-Cas9 therapies in experimental mouse models of cancer. Estêvão D; Rios Costa N; da Costa RG; Medeiros R Future Oncol; 2018 Aug; 14(20):2083-2095. PubMed ID: 30027767 [TBL] [Abstract][Full Text] [Related]
17. The potential of gene editing for Huntington's disease. Duan W; Urani E; Mattson MP Trends Neurosci; 2023 May; 46(5):365-376. PubMed ID: 36907678 [TBL] [Abstract][Full Text] [Related]
18. The Hope and Hype of CRISPR-Cas9 Genome Editing: A Review. Musunuru K JAMA Cardiol; 2017 Aug; 2(8):914-919. PubMed ID: 28614576 [TBL] [Abstract][Full Text] [Related]
19. The application of somatic CRISPR-Cas9 to conditional genome editing in Caenorhabditis elegans. Li W; Ou G Genesis; 2016 Apr; 54(4):170-81. PubMed ID: 26934570 [TBL] [Abstract][Full Text] [Related]
20. Genome editing for the reproduction and remedy of human diseases in mice. Hara S; Takada S J Hum Genet; 2018 Feb; 63(2):107-113. PubMed ID: 29180644 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]